Recent Updates
Recently added Catalysts
BBIO

BridgeBio Pharma Announces Publication Of Positive Results From Phase 3 ATTRibute-CM Study Of Acoramidis In The New England Journal Of Medicine

Wednesday, January 10, 2024 1 min read
Key Takeaway: BridgeBio Pharma Announces Publication Of Positive Results From Phase 3 ATTRibute-CM Study Of Acoramidis In The New England Journal Of Medicine

Full Press Release Details

BridgeBio Pharma Announces Publication Of Positive Results From Phase 3 ATTRibute-CM Study Of Acoramidis In The New England Journal Of Medicine.
Tags: BBIO Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 10, 2024